The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Tuzodi midazolam | Regulatory Pharma Net S.r.l. | Seizures | 🇪🇺 EU | Order → |
| Tyvaso treprostinil sodium Orphan | United Therapeutics Europe Ltd | Hypertension, Pulmonary | 🇪🇺 EU | Order → |
| Ubeslo obicetrapib | A. Menarini International Licensing S.A. | Hypercholesterolemia; Dyslipidemias | 🇪🇺 EU 2026-07-23 | Order → |
| Upkanz deferiprone Orphan | Apotex B.V. | Pantothenate Kinase-Associated Neurodegeneration | 🇪🇺 EU | Order → |
| Upstelda ustekinumab | Amgen Technology (Ireland) UC | Psoriasis; Arthritis, Psoriatic; Crohn Disease | 🇪🇺 EU | Order → |
| Valdoxan agomelatine | Les Laboratoires Servier | Depressive Disorder, Major | 🇪🇺 EU 2006-07-27 | Order → |
| Vanflyta quizartinib | Daiichi Sankyo Europe GmbH | Leukemia, Myeloid, Acute | 🇪🇺 EU 2019-10-17 | Order → |
| VaxRabeo rabies vaccine (inactivated) for human | Sanofi Winthrop Industrie | Rabies | 🇪🇺 EU 2026-09-17 | Order → |
| Veblocema infliximab | Celltrion Healthcare Hungary Kft. | Arthritis, Rheumatoid; Crohn Disease; Colitis, Ulcerative | 🇪🇺 EU | Order → |
| Vekacia ciclosporin Orphan | Novagali Pharma S.A. | Conjunctivitis, Allergic | 🇪🇺 EU | Order → |
| Veraseal human fibrinogen;human thrombin | Instituto Grifols, S.A. | Hemostasis, Surgical | 🇪🇺 EU | Order → |
| Vibativ telavancin | Astellas Pharma Europe B. V. | Skin Diseases, Infectious; Staphylococcal Infections; Soft Tissue Infections | 🇪🇺 EU | Order → |
| Vijoice alpelisib Orphan | Novartis Europharm Limited | Genetic Diseases, Inborn; Growth Disorders | 🇪🇺 EU | Order → |
| Viokat diazoxide choline Orphan | Prader-Willi Syndrome | 🇪🇺 EU 2026-04-23 | Order → | |
| Vitragan hyaluronidase | ISTA Pharma Limited | Vitreous Hemorrhage | 🇪🇺 EU | Order → |
| Vivjoa oteseconazole | Gedeon Richter Plc. | Candidiasis | 🇪🇺 EU | Order → |
| Voraxaze glucarpidase Orphan | Protherics PLC | 🇪🇺 EU | Order → | |
| Vorinostat MSD vorinostat | Merck Sharp Dohme Limited | Lymphoma, T-Cell, Cutaneous | 🇪🇺 EU | Order → |
| Vynfinit | Endocyte Europe, B.V. | Ovarian Neoplasms | 🇪🇺 EU | Order → |
| Vynpenta (previously AvacopanChemoCentryx) avacopan Orphan | ChemoCentryx Ltd | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.